LONDON (AP) _ Myovant Sciences Ltd. (MYOV) on Tuesday reported a loss of $59.3 million in its fiscal fourth quarter.

The London-based company said it had a loss of 63 cents per share.

The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 55 cents per share.

The biopharmaceutical company posted revenue of $57.6 million in the period.

For the year, the company reported that its loss narrowed to $206 million, or $2.22 per share. Revenue was reported as $231 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MYOV at https://www.zacks.com/ap/MYOV

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News